Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...

T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

In a significant step forward for India’s cancer treatment, Immuneel Therapeutics, a leading cell and gene therapy statrtup backed by entrepreneur Kiran Mazumdar-Shaw, has unveiled Qartemi, the ...

Ubisoft is apparently endeavoring to work with Tencent to bring forth new ventures, one of which is the rumored Splinter Cell Remake. During an address, Guillemot confirmed numerous titles were in ...

Scientists have revealed the secret to the structural integrity of tiny particles that transport cargo from cell to cell through ... and cardiovascular disease, cancer and neurological disorders.

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery. Adjuvant treatment with cemiplimab (Libtayo ...